|
1
|
Abdullah JM, Jing X, Spassov DS, Nachtman
RG and Jurecic R: Cloning and characterization of Hepp, a novel
gene expressed preferentially in hematopoietic progenitors and
mature blood cells. Blood Cells Mol Dis. 27:667–676. 2001.
View Article : Google Scholar
|
|
2
|
Walker MG: Drug target discovery by gene
expression analysis: Cell cycle genes. Curr Cancer Drug Targets.
1:73–83. 2001. View Article : Google Scholar
|
|
3
|
Lai IL, Wang SY, Yao YL and Yang WM:
Transcriptional and subcellular regulation of the TRIP-Br family.
Gene. 388:102–109. 2007. View Article : Google Scholar
|
|
4
|
Watanabe-Fukunaga R, Iida S, Shimizu Y,
Nagata S and Fukunaga R: SEI family of nuclear factors regulates
p53-dependent transcriptional activation. Genes Cells. 10:851–860.
2005. View Article : Google Scholar
|
|
5
|
Cheong JK, Gunaratnam L, Zang ZJ, Yang CM,
Sun X, Nasr SL, Sim KG, Peh BK, Rashid SB, Bonventre JV, et al:
TRIP-Br2 promotes oncogenesis in nude mice and is frequently
overexpressed in multiple human tumors. J Transl Med. 7:82009.
View Article : Google Scholar :
|
|
6
|
Tang DJ, Hu L, Xie D, Wu QL, Fang Y, Zeng
Y, Sham JS and Guan XY: Oncogenic transformation by SEI-1 is
associated with chromosomal instability. Cancer Res. 65:6504–6508.
2005. View Article : Google Scholar
|
|
7
|
Hsu SI, Yang CM, Sim KG, Hentschel DM,
O'Leary E and Bonventre JV: TRIP-Br: A novel family of PHD zinc
finger- and bromodomain-interacting proteins that regulate the
transcriptional activity of E2F-1/DP-1. EMBO J. 20:2273–2285. 2001.
View Article : Google Scholar :
|
|
8
|
Li C, Jung S, Lee S, Jeong D, Yang Y, Kim
KI, Lim JS, Cheon CI, Kim C, Kang YS and Lee MS: Nutrient/serum
starvation derived TRIP-Br3 down-regulation accelerates apoptosis
by destabilizing XIAP. Oncotarget. 6:7522–7535. 2015. View Article : Google Scholar :
|
|
9
|
Hong SW, Kim CJ, Park WS, Shin JS, Lee SD,
Ko SG, Jung SI, Park IC, An SK, Lee WK, et al: p34SEI-1 inhibits
apoptosis through the stabilization of the X-linked inhibitor of
apoptosis protein: p34SEI-1 as a novel target for anti-breast
cancer strategies. Cancer Res. 69:741–746. 2009. View Article : Google Scholar
|
|
10
|
Hayashi R, Goto Y, Ikeda R, Yokoyama KK
and Yoshida K: CDCA4 is an E2F transcription factor family-induced
nuclear factor that regulates E2F-dependent transcriptional
activation and cell proliferation. J Biol Chem. 281:35633–35648.
2006. View Article : Google Scholar
|
|
11
|
Tategu M, Nakagawa H, Hayashi R and
Yoshida K: Transcriptional co-factor CDCA4 participates in the
regulation of JUN oncogene expression. Biochimie. 90:1515–1522.
2008. View Article : Google Scholar
|
|
12
|
Lee SL, Hong SW, Shin JS, Kim JS, Ko SG,
Hong NJ, Kim DJ, Lee WJ, Jin DH and Lee MS: p34SEI-1 inhibits
doxorubicin-induced senescence through a pathway mediated by
protein kinase C-delta and c-Jun-NH2-kinase 1 activation in human
breast cancer MCF7 cells. Mol Cancer Res. 7:1845–1853. 2009.
View Article : Google Scholar
|
|
13
|
Alderman C, Sehlaoui A, Xiao Z and Yang Y:
MicroRNA-15a inhibits the growth and invasiveness of malignant
melanoma and directly targets on CDCA4 gene. Tumour Biol.
37:13941–13950. 2016. View Article : Google Scholar
|
|
14
|
Wang XJ, Sun Z, Villeneuve NF, Zhang S,
Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, et al: Nrf2
enhances resistance of cancer cells to chemotherapeutic drugs, the
dark side of Nrf2. Carcinogenesis. 29:1235–1243. 2008. View Article : Google Scholar :
|
|
15
|
Livak KJ and Scmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar
|
|
17
|
Wang L, Zhu G, Li Q, Li Y, Xu X, He D and
Zeng C: The spindle function of CDCA4. Cell Motil Cytoskel.
65:581–593. 2008. View
Article : Google Scholar
|
